MW-150
MW-150 性质
| 沸点 | 606.1±55.0 °C(Predicted) |
|---|---|
| 密度 | 1.202±0.06 g/cm3(Predicted) |
| 储存条件 | Store at -20°C |
| 溶解度 | DMSO：40 mg/mL（104.86 mM；需要超声波） |
| 形态 | 固体 |
| 酸度系数(pKa) | 7.16±0.42(Predicted) |
MW-150 用途与合成方法
|
p38α 101 nM (Ki) |
MW-150 inhibits in a concentration-dependent manner the ability of the endogenous p38α MAPK to phosphorylate an endogenous substrate MK2 in activated glia.
MW-150 blocks in a concentration-dependent manner the increased IL-1β production by activated glia. The IC
50
values are 332 nM and 936 nM for MK2 and IL-1β, respectively.
MW-150 (2.5 mg/kg; oral daily for 3-4 months) improves the APP/PS1 transgenic (Tg) mice performance in radial arm water maze (RAWM) and contextual fear conditioning tests.
MW-150 (2.5 mg/kg; given i.p.; daily for 14 days) treatment in APP
NLh/NLh
× PS
P264L/P264L
knock-in mouse (with no overexpression of the amyloid precursor protein) exhibits RAWM behavior indistinguishable from WT mice.
| Animal Model: | APP/PS1 transgenic (Tg) mouse (overexpresses amyloid-beta) |
| Dosage: | 2.5 mg/kg |
| Administration: | Oral daily; 3-4 months (until cognitive impairment is present) |
| Result: | Improved the Tg mice performance in radial arm water maze (RAWM) and contextual fear conditioning tests. |
MW-150 价格(试剂级)
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2024-01-25 | HY-120111 | 1 mg | 433 | ||
| 2024-01-25 | HY-120111 | MW-150 | 1628502-91-9 | 5mg | 1300 |
